VISEN Pharmaceuticals (HKG:2561) reported 118 million yuan in attributable loss for the first half of 2025, widening by 41% from a loss 83.5 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.

Loss per share was 1.18 yuan, compared with 0.89 yuan in the prior year.

It came as the company, which debuted on the Hong Kong bourse in March, continues to develop its core product called lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency.

In July, the company partnered with Anhui Anke Biotechnology (SHE:300009) to jointly promote the drug in specific regions of China.

Shares of the pharmaceutical company fell 1.1% in midday trade Thursday.